Cipla & Formosa Ink Licensing Deal for Clobetasol Suspension Kumar Jeetendra | March 18, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals (6838.TW) for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007). Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries …
Revolutionizing Infectious Disease: Dr. Paul’s Journey Kumar Jeetendra | May 12, 2025 In this captivating episode of our podcast series, we feature the world-renowned microbiologist, inventor, and thought leader in anti-infectives and infectious disease R&D, Dr. Maneesh Paul. Key Highlights: The story of Enmetazobactam – India’s first indigenously developed anti-infective and its journey from concept to global approvals (DCGI, USFDA, UKMHRA, EMA). Aspects of AMR, Planetary Health, …
Spotlight on Women Leaders: Special Edition by Microbioz India Kumar Jeetendra | June 1, 2025 It is with utmost pride that Microbioz India announces the release of a new special edition dedicated to Leading Women in Pharma and Healthcare. This exclusive edition dedicated to women in pharma and healthcare genres highlights the remarkable contributions and influences from women who are spearheading the innovations in the Pharma and Healthcare ecosystem. We …
Accuracy and Speed: Science Driving J Mitra’s Rapid Test Kits Kumar Jeetendra | June 6, 2025 With a stellar legacy spanning over five decades, 55 patents, and exports to more than 45 countries, J Mitra and Company has become a worldwide pioneer in the in-vitro diagnostics (IVD) sector. The company has developed a solid reputation for creativity, quality, and affordability in diagnostic solutions. J Mitra focuses on enhancing the speed and …
Cipla Invests in iCaltech to Boost Respiratory Portfolio Kumar Jeetendra | July 22, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has signed definitive agreements for investment in Optionally Convertible Preference Shares of iCaltech Innovations Private Limited (hereafter referred to as “iCaltech”), subject to completion of certain conditions. Cipla Invests in iCaltech to Strengthen Respiratory Diagnostics Ecosystem in India …
Jodi Barrientos on Leading Synthetic Biology’s Next Wave Kumar Jeetendra | October 6, 2025 Microbioz India recently hosted a podcast in which Jodi Barrientos, CEO of Ribbon Bio, very eloquently described her career path, her thoughts on the future of synthetic bio, and the change(s) she hopes to implement in our industry. Jodi Barrientos spent 17 years in the commercial sector, exceeding the expectations of some of the world’s …
